41 results about "Francisella tularensis" patented technology

The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.

The invention provides a reagent for detecting francisella tularensis. The reagent comprises an upstream primer, a downstream primer, a fluorescent probe and a quenching probe, wherein the gene sequence FTF1 of the upstream primer is 5'-aagcaagtgttgactacagat-3', the gene sequence FTR1 of the downstream primer is 5'-caccaaagaaccatgttaaac-3', the gene sequence FPFT1 of the fluorescent probe is 5'-FAM-aatcatgttagtacccgctctgcca-p-3', and the gene sequence QPFT1 of the quenching probe is 5'-agcgggtactaacatgat-Dabcyl-3'. The invention also provides a complex probe and fluorescent quantitative PCR method for detecting the francisella tularensis by using the reagent. Compared with the traditional francisella tularensis detecting technology, the invention has the advantages of simple operation, high efficiency, quickness and high specificity.

The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.

Described herein is the identification of nucleotide sequences specific to Francisella tularensis that serves as a marker or signature for identification of this bacterium. In addition, forward and reverse primers and hybridization probes derived from these nucleotide sequences that are used in nucleotide detection methods to detect the presence of the bacterium are disclosed.

The invention relates to the areas of therapeutics, pharmaceuticals, drug discovery, and immunotherapy. More specifically, the present invention relates to methods of stimulating the immune system through the administration of flavone acetic acid [FAA] analogues, and in particular, the flavone acetic acid analogue, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) so as to comprise an antimicrobial therapeutic agent for the treatment of viral, fungal, bacterial or parasitic infections in humans and non-human animals. The invention is especially suitable for use in a process of treating and preventing infection by viruses (for example, rhinoviruses, enteroviruses, and influenza viruses, etc.) and bacteria (especially intracellular bacterial pathogens such as Francisella tularensis).

A method for simultaneous detection and identification of Bacillus anthracis, Yersinia pestis and Francisella tularensis, in a single real time PCR assay using species-specific primers and Taqman MGB probes. Also, a kit for the diagnosis of bacterial bioterrorism agents. In addition, an infection-free control plasmid to verify the result of the real time PCR analysis method.

A method of detecting a presence of Francisella tularensis (F. tularensis). The method includes amplifying a first nucleic acid from said specimen using a first plurality of primers, said first plurality of primers comprising SEQ ID NO 4 and SEQ ID NO 5. When the first nucleic acid is detected, then the presence of F. tularensis is determined.

The invention discloses a genetic liquid phase chip for rapid detection of five drastic pathogenic bacteria of bacillus anthracis, yersinia pestis, brucella bacteria, francisella tularensis and burkholderia pseudomallei. The liquid phase chip for detecting the five drastic pathogenic bacteria has the advantages of large flux, less required sample capacity, strong specificity, high sensitivity, accuracy, high efficiency, and the like.

The present invention relates to a mutant Francisella tularensis strain comprising an inactivated clpB gene and compositions comprising such mutant. Methods of producing the mutant are also described. The present invention also encompasses a method of conferring immunity against F. tularensis in a host, comprising administering the described mutant F. tularensis strain.

A mutant strain of Francisella tularensis has attenuated virulence and has a mutation in the gene coding for a putative peroxynitrite resistance protein A (prpA) which prevents normal function of the protein. The mutant is useful as a vaccine against type A and B virulent strains of F. tularensis, and is produced by obtaining a virulent F. tularensis strain and mutating the gene, FTT0918, that codes for prpA.

This invention discloses methods for identifying Francisella tularensis vaccine candidates. It enables identification of novel vaccine candidates and quality assurance for vaccine batches, assessment of protection in vaccinates and identification of the infecting agent in vaccinates. Mice were first vaccinated with Brucella abortus O-polysaccharide (OPS) vaccine. These animals were then given 10 LD50s of F. tularensis live vaccine strain (LVS). Sixty percent (60%) of the vaccinated mice survived the multiple lethal doses. Sera were collected from these surviving mice and the antibodies were used to probe supernatant and cell lysates of live F. tularensis LVS cultures. Several F. tularensis components were identified only by the noted “survivor” antisera. Of these identified proteins, enzyme digestions and chemical oxidation suggest post-translational modifications of some proteins e.g. a 52 kDa glycoprotein, a 45 kDa lipoprotein and a 19 kDa nucleoprotein. The 52 kDa component caused nitrous oxide induction in tissue cultures at low concentrations, cell death at high concentrations. Vaccination with this gave partial protection while addition of other components acted synergistically to give enhanced protection from 250 LD50s of F. tularensis LVS.

The invention relates to methods for the preparation of a pharmaceutical-vesicle formulation comprising steps of: preparing and processing vesicle components and a pharmaceutical agent to entrap the pharmaceutical agent in the vesicle and form a pharmaceutical-vesicle formulation, wherein the pharmaceutical-vesicle formulation is reconstituted in a known quantity of the pharmaceutical agent dissolved in a pharmaceutically-acceptable carrier to provide a biphasic pharmaceutical-vesicle formulation. The invention also relates to the associated pharmaceutical-vesicle formulations, pharmaceutical kits and uses as a medicament, in particular for the prevention or treatment of infection by bacteria such as Burkholderia pseudomallei and Francisella tularensis, and viruses such as Venezuelan Equine Encephalitis Virus (VEEV).

The invention discloses a CRISPR-Cas12a detection primer group for francisella tularensis and an application thereof. The invention provides the primer group for detecting francisella tularensis and is composed of an RPA primer pair and crRNA; the RPA primer pair is designed according to the nucleotide sequence shown in SEQ ID NO.1 in the francisella tularensis genome; the crRNA comprises an anchoring sequence and a guide sequence, wherein the anchoring sequence can be combined with a cas protein, and the guide sequence is matched with an amplification product sequence of an RPA primer pair. The detection primer group has the characteristics of short detection time, high amplification efficiency, high sensitivity, strong specificity and the like, and the detection sensitivity on francisella tularensis positive plasmids can reach 900 copy / ml, and the detection sensitivity on the francisella tularensis genome can reach 1260 fg / mL. The francisella tularensis onsite diagnosis method has awide application prospect.

The invention relates to a method of detecting Francisella tularensis by a multiple PCR technique, belonging to the technical field of detecting biological agent. The invention comprises steps of: using the related genes lpxF, lpxE and flmK of the endotoxin of the Francisella tularensis as the specificity targets, carrying out comparison by complete sequence Blastp of NCBI microbial genome to determine the specificities of the three genes, designing the related primer and conducting detection by the multiple PCR technique; after three strips, which are 447bp,717bp and 1004bp in turn, appear in the electrophoresis detection, judging the strips to be masculine according to the appearance of three specificity strips, otherwise, judging the strips to be feminine. The invention has the advantages of simple and convenient operation, easy promotion and application, short detecting cycle, high sensitivity, good specificity and higher detecting rate, wherein, with respect to 5 to 7 days neededto obtain the result by the traditional detecting method, the detecting cycle of the method, which is 3 hours, is much shorter than that of the traditional method, thus greatly improving the detecting efficiency; moreover, the detecting limit, which is 0.01ng / [mu]L and 5X10<5>cfu / mL, reaches or exceeds that of the traditional detecting method.

The invention discloses a PCR primer pair for rodent-borne disease pathogenic microorganisms. The primer pair is used for amplifying specific genes of leptospira interrogans, Rickettsi Mooseri, Orientia tsutsugamushi, anaplasma phagocytophilum, francisella tularensis, Coxiella burnetii and Bartonella. By adopting the PCR primer pair, on the basis of the TSP principle, the method for high-sensitiveand specific independent or combined detection of the seven kinds of pathogene.